Pluri Inc. Logo

Pluri Inc.

Develops cell therapies from placental cells for inflammatory & hematologic disorders.

PLUR | US

Overview

Corporate Details

ISIN(s):
US72940R3003
LEI:
Country:
United States of America
Address:
MATAM ADVANCED TECHNOLOGY PARK, 0 HAIFA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company specializing in the research, development, and manufacturing of cell-based products and therapeutics. The company leverages proprietary 3D cell-expansion technology platforms to create solutions from human placental cells. Pluri aims to improve human well-being and sustainability by developing therapies for various conditions, including ischemic, inflammatory, and hematologic disorders. It collaborates with research partners and academic institutions to advance its cell-based product pipeline for commercial use.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pluri Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pluri Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America CNTX
Contineum Therapeutics, Inc. Logo
Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.
United States of America CTNM
CORCEPT THERAPEUTICS INC Logo
Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.
United States of America CORT

Talk to a Data Expert

Have a question? We'll get back to you promptly.